BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene The
false
ביוליין אר אקס בע"מ
2
380
BIOLINE RX LTD
Corporation no:
513398750
8688
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
21/12/2023
www.isa.gov.il
www.tase.co.il
Reference:
2023-02-138897
Time of broadcast:
11:26
11:26
The corporation scheduled the publication of the report to
21/12/2023 14:06
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
6-K_21-Dec-23_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
NASDAQ CM
Date of revision of form structure:
05/12/2023
Address:
HaMa'ayan
2
,
Modi'in
7177871
,
Israel
Tel:
08-6429100
,
Fax:
08-6429101
E-mail address:
info@BioLineRx.com
Company site:
www.biolinerx.com
Previous names of reporting entity:
Name of the Signatory:
Serlin Philip Adam
Position of Signatory in the reporting corporation:
Chief Executive Officer
Name of Employer Company:
Address:
HaMa'ayan
2
,
Modi'in
7177871
Telephone:
08-6429100
Facsimile:
08-6429101
E-mail:
phils@biolinerx.com
1
Israel